According to Gram Research analysis, scientists identified FES, a protein in immune cells, as a new potential treatment for atherosclerosis (clogged arteries). In laboratory mice, increasing FES levels significantly reduced inflammation and fatty plaque buildup in arteries by activating a protective chain reaction involving the PU.1 and Arg1 proteins. While this research is promising, human testing is needed before any FES-based therapy could become available.
Scientists discovered that a protein called FES, found in immune cells, plays a key role in preventing heart disease caused by clogged arteries. Using advanced genetic analysis and lab experiments, researchers found that boosting FES levels in mice reduced inflammation and plaque buildup in arteries. The study suggests that FES could become a new treatment approach for atherosclerosis, the condition where fatty deposits narrow blood vessels. This research combines genetic data from thousands of people with laboratory testing to identify a promising new target for fighting one of the world’s leading causes of heart disease.
Key Statistics
A 2026 research article published in the International Journal of Biological Macromolecules identified FES tyrosine kinase as a novel therapeutic target for atherosclerosis using genetic analysis of thousands of people combined with laboratory mouse studies.
In laboratory mice with atherosclerosis, intravenous delivery of a gene therapy vector carrying FES significantly reduced inflammatory responses and lipid deposition in arterial plaques compared to control mice.
Researchers discovered that FES exerts its protective effect by activating the transcription factor PU.1, which then increases expression of Arg1, a protein known to reduce inflammation and promote healing in atherosclerotic plaques.
The Quick Take
- What they studied: Whether a protein called FES could help prevent atherosclerosis (clogged arteries that cause heart disease)
- Who participated: The research used genetic information from thousands of people in databases, plus laboratory mice with a condition that mimics human heart disease
- Key finding: When researchers increased FES levels in mice, it significantly reduced inflammation and fatty buildup in their arteries, suggesting FES could be a new treatment target
- What it means for you: This research is early-stage but promising. It identifies a new potential therapy for heart disease, though human testing would be needed before any treatment becomes available. People at risk for heart disease should continue following proven prevention strategies like exercise and healthy eating.
The Research Details
This study used multiple research approaches to identify FES as a potential heart disease treatment. First, scientists performed a genetic analysis called Mendelian randomization, which uses large databases of genetic information to find which proteins might cause disease. They analyzed genetic data from FinnGen (a Finnish database) and protein information from the UK Biobank, looking for connections between specific proteins and atherosclerosis risk.
Next, they used single-cell expression profiling to see which cells in the body make FES protein. Finally, they tested their findings in laboratory mice that had been genetically modified to develop atherosclerosis when fed a high-fat diet. The researchers injected a modified virus carrying extra copies of the FES gene into these mice to see if increasing FES levels would reduce disease.
This multi-step approach is powerful because it combines human genetic evidence with laboratory experiments. The genetic analysis shows what happens in real people, while the mouse experiments allow researchers to test whether increasing FES actually causes the protective effect. This combination makes the findings more reliable than either approach alone.
Strengths: The study uses large human genetic databases and confirms findings in animal models. The researchers used multiple validation methods including computational predictions and biochemical experiments. Limitations: The study hasn’t been tested in humans yet, only in mice. The exact sample size from genetic databases isn’t specified. Results in mice don’t always translate to humans, so more research is needed before any clinical application.
What the Results Show
The researchers discovered that FES protein levels were significantly lower in atherosclerotic plaques (the fatty deposits in arteries) from mice with heart disease compared to healthy mice. When they increased FES levels using gene therapy, the results were striking: inflammation in the plaques decreased substantially, and the amount of lipid (fat) buildup was significantly reduced.
The protective effect worked through a specific mechanism. FES activated a protein called PU.1, which then increased production of another protein called Arg1. Arg1 is known to reduce inflammation and promote healing. This chain reaction—FES → PU.1 → Arg1—appears to be how FES protects against atherosclerosis.
The findings suggest that FES acts as a natural brake on the inflammatory processes that drive atherosclerosis. By boosting FES, researchers essentially strengthened this natural protection system.
The study identified that FES works specifically in macrophages, which are immune cells that play a central role in atherosclerosis. The researchers found that FES increases Arg1 expression by promoting the movement of PU.1 (a transcription factor) into the cell nucleus, where it can activate genes. This detailed understanding of the mechanism makes FES a more attractive therapeutic target because researchers understand exactly how it works.
This is the first study to identify FES as having a protective role in atherosclerosis. Previous research has focused on other immune mechanisms in heart disease, but FES’s role in macrophages and its connection to the PU.1/Arg1 pathway appears to be novel. The findings fit with existing knowledge that reducing inflammation and promoting alternative macrophage activation (which Arg1 does) can slow atherosclerosis progression.
The study was conducted entirely in mice and genetic databases—no human clinical trials have been performed. Results in mice often don’t translate directly to humans due to differences in metabolism and physiology. The gene therapy approach used (injecting a modified virus) would need significant development before it could be tested in patients. The study doesn’t address whether this approach would work in people with existing atherosclerosis or only in prevention. Long-term safety of FES overexpression hasn’t been evaluated.
The Bottom Line
This research is promising but preliminary. Current evidence-based recommendations for preventing atherosclerosis remain: maintain a healthy diet low in saturated fat, exercise regularly, maintain a healthy weight, don’t smoke, and manage blood pressure and cholesterol. This FES research may eventually lead to new treatments, but that’s likely years away. People with family history of heart disease should discuss their risk with a doctor.
This research is most relevant to people at high risk for atherosclerosis, including those with family history of early heart disease, high cholesterol, high blood pressure, or diabetes. Cardiologists and cardiovascular researchers should pay attention as this could lead to new therapeutic approaches. The general public should be aware this is early-stage research that may eventually improve heart disease treatment, but shouldn’t expect immediate clinical applications.
This research is in the laboratory stage. If FES-based therapies move forward, typical development timelines suggest 5-10 years before human clinical trials could begin, and potentially 10-15 years before any new treatment might become available to patients. Continued research is needed to confirm these findings and develop safe delivery methods for humans.
Frequently Asked Questions
What is FES and why does it matter for heart disease?
FES is a protein found in immune cells called macrophages. Research shows that FES reduces inflammation and fatty buildup in arteries by activating protective proteins. Low FES levels appear in people with atherosclerosis, making it a promising new treatment target for preventing heart disease.
Can I get FES treatment for atherosclerosis now?
No, FES-based treatments are still in early laboratory stages. This research used mice and genetic databases, not human patients. Typical drug development takes 10-15 years, so any FES therapy would likely not be available for many years. Continue following proven prevention strategies like exercise and healthy diet.
How does FES actually prevent clogged arteries?
FES works by activating a protein called PU.1, which increases production of Arg1. Arg1 reduces inflammation and promotes healing in arteries. This chain reaction—FES activating PU.1 to increase Arg1—appears to be nature’s built-in protection against atherosclerosis that weakens when FES levels drop.
Should I change my lifestyle based on this FES research?
No immediate lifestyle changes are needed based on this research alone. Continue proven heart disease prevention: exercise 150 minutes weekly, eat a heart-healthy diet low in saturated fat, maintain healthy weight, manage blood pressure and cholesterol, and don’t smoke. This FES research may eventually enhance these strategies.
Who is most likely to benefit from FES therapy when it becomes available?
People at high risk for atherosclerosis would likely benefit most: those with family history of early heart disease, high cholesterol, high blood pressure, diabetes, or who smoke. However, FES therapy is still theoretical and hasn’t been tested in any human patients yet.
Want to Apply This Research?
- Track cardiovascular risk factors: weekly blood pressure readings, monthly cholesterol levels (if available through home testing), daily steps/activity minutes, and weekly servings of heart-healthy foods like fish and vegetables. Monitor these metrics to establish baseline and track improvements from lifestyle changes.
- Users can set goals to increase physical activity to 150 minutes weekly, reduce saturated fat intake, increase fiber consumption, and maintain healthy blood pressure. The app could send reminders about these evidence-based prevention strategies while noting that new treatments like FES-based therapies are in development.
- Create a long-term cardiovascular health dashboard tracking: weekly exercise minutes, daily diet quality score, monthly blood pressure and cholesterol (if self-testing), weight trends, and stress levels. Compare these metrics quarterly to show progress in modifiable risk factors while awaiting future therapeutic developments.
This article describes early-stage laboratory research that has not been tested in humans. FES-based treatments are not currently available and may never become clinically available. This information is for educational purposes only and should not replace professional medical advice. Anyone concerned about heart disease risk should consult with a healthcare provider about proven prevention strategies including diet, exercise, and medication if appropriate. Do not delay or avoid seeking medical care based on this research.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.